Curious about who I am? Posts about health and natural birth Resources and posts regarding vaccines and informed consent Posts about Parenting and Relationships Spirituality and Life Lessons Email me Home
Showing posts with label mutation. Show all posts
Showing posts with label mutation. Show all posts

The Perfect Storm - How the increase in pertussis vaccine usage is causing an 'epidemic'

If you live in the United States then you and your children most likely have had at least one pertussis (DTP, DTaP, Tdap) vaccination – fair to say, that you’ve had multiple injections over your lifetime…and you are urged to continue to get them.

According to the CDC, despite the high vaccination rates, the number of reported cases of pertussis has increased steadily since the 1980s. [1]


Curious enough, we are experiencing the highest vaccination rates against pertussis ever recorded in the US.

Then what the heck is going on? Shouldn’t we be seeing a decline…or at the very least no increase.

Lucky for us, there is a scientific library accumulating as we speak with published works about the Bordetella spp. bacteria and acelluar vaccines- one which might have us considering the increase in vaccine usage is contributing to a combination of circumstances that is causing a rise in Bordetella infections.

A perfect storm.

A "perfect storm" is an expression that describes an event where a combination of circumstances will aggravate a situation drastically.


So, what could be the circumstances contributing to the increase in pertussis/parapertussis infections in the United States… (reiterating here: even with the highest rates of vaccine coverage ever experienced)?

Can you think of any? I can -



Vaccinated population as asymptomatic carriers of pertussis

To understand this factor we have understand an important aspect of illness: clinical stages of disease.

Pertussis is an acute infection of the upper respiratory tract caused by Bordetella bacteria (B. pertussis and in some cases B. parapertussis) which last approximately 6 week and has three clinical stages.

The initial stage resembles a common cold with a mild cough, followed by the second (paroxysmal) stage that is characterized by the repetitive episodes of coughing fits and the typical “whoop” cough. The final stage lasts 1-2 weeks and marks a decrease in the frequency and severity of the cough.[2]


It has been recurrently documented (and touted as a benefit to getting vaccinated) that infected vaccinated individuals will suffer a milder, nonspecific form of the disease. Specifically, infections in the vaccinated population cause nonspecific symptoms.

Vaccinated adolescents and adults become reservoirs for silent infection and transmitters. [3][4][5][6][7][8]



Pertussis vaccination increases susceptibility and enhances performance for B.parapertussis bacteria.


There are 3 species of Bordetella bacteria that are human pathogens, however only the B. Pertussis and B. Parapertussis can cause whopping cough in humans.

The pertussis (aP) vaccination not only makes a person more susceptible to B. parapertussis infection but it enhances the performance of the pathogen. [9]


Research has illustrated a 40-fold increase in B. parapertussis lung colony-forming units after vaccination of aP injections.[9]

A little side note about evolution here (because evolution is neat to learn about)- because of the O-antigen that is found only on B. parapertussis, immunity derived from B. pertussis does not protect against infection by B. parapertussis. The parapertussis bacteria are free to colonize a host's lungs without being subject to attack by previous pertussis antibodies. This particular finding suggests that B. parapertussis evolved in a host population that had already developed immunity to B. pertussis, where being able to evade B. pertussis immunity was an advantage.[10]

If I was a gambling woman, I would bet that we will be subjected to a parapertussis vaccine within the next 8 years.



Increase in antibiotic resistance with a standstill in new research & development


Antibiotic treatment plays an important role in treatment of pertussis and parapertussis in the United States. Erythromycin helps eliminate the Bordetella organism from the respiratory tract and is currently the treatment of choice for patients with confirmed and pertussis and their close contacts.[11]


The first case of erythromycin-resistant B. pertussis was identified in Yuma, Arizona in 1994. To-date, four additional cases of erythromycin-resistant B. pertussis have been reported in the United States. Most recently, screening of 1,030 isolates of B. pertussis revealed an additional five strains exhibiting a heterogeneous erythromycin resistance phenotype.[11]
 

As you might know, antibiotic-resistant bacteria make it difficult—sometimes impossible—to treat serious infections.[12]


This is because when certain antibiotics are used to kill bacteria, a few may survive because they happen to have the appropriate genes; thus they will become the predominant strain. For example, if an antibiotic kills ten million bacteria but doesn’t kill five that are resistant, at their incredible multiplication rate (bacteria divide approximately every 20 minutes) after 15 hours there will be 5 million descendants of those five, all of them resistant to the antibiotic.[12] 

Neat huh? Some bacteria even carry antibiotic resistance genes that can be passed to other species of bacteria.[12]

Not so good news? New antibiotic drug development and research is stalling. The main reason behind this is because pharmaceutical companies don’t have very many incentives for developing antibiotic drugs. Why focus on research for drugs that people will only take for a few days versus development on drugs for chronic illnesses such as arthritis and heart disease which people will take for years?[13]



Vaccine Failure

Children in the United States receive five doses of diptheria, tetanus and (aP) pertussis (DTaP) vaccine before the age of 7, yet duration and effectiveness protection is unknown.[14]


To reiterate, despite high vaccination rates, the number of reported cases of pertussis in the United States has increased steadily since the 1980s.[1]

This rate of exacerbations has not changed, even after the introduction of mass vaccination – a fact that indicates the vaccine does not prevent transmission of the causative agent (B. pertussis) within the population [15]


Despite detailed analysis of several virulence-associated factors of B. pertussis, significant gaps remain in the understanding of the pathogenesis of the infection and disease. [16]

Something that is becoming more evident and important in understanding why the vaccine is much less effective then believed is that clinical efficacy trials of the (aP) pertussis vaccines did not yield any correlation between antibody levels and protection against pertussis.[17]

The mechanisms of vaccine-induced immunity remain elusive. [17]

The current vaccines contain antigenic components for 3 pertussis antigens (Filamentous hemagglutinin, Pertactin, and the pertussis toxin itself [PT]). [17]

Unfortunately, research of the pathogensis of infection confirms that the vaccine is omitting a vital toxin. The adenylate cyclase toxin (CyaA or also known as ACT).[15][16]

Despite the widespread national childhood vaccination program against B pertussis, the disease remains prevalent.[18]


And despite over 50 years of this population-wide vaccination, whooping cough incidence is on the rise.[9]




The new 2013 recommendation for pregnant moms


The CDC confirms that more than 41,000 cases of whooping cough were reported last year, the highest level in more than 50 years and more than double the 2011 total.[19]


The disease was linked to 18 deaths in 2012, with the majority of them babies younger than 3 months old.[19]

The CDC and ACIP no longer demands a superior vaccine-instead the latest recommendation is to vaccinated pregnant mothers - during EACH and EVERY pregnancy.[19]

This is contrary to what the manufacture shave proven is safe and what is approved by the FDA. However, doctors do not need FDA approval to recommend and administer the vaccine repeatedly to pregnant women.[19][20]

In fact, there is no data at all to support repeat administration of Tdap in any population, especially pregnant women.[20] 


This should be cause for concern for anyone that just read this post for one main reason (1) due to the vaccine causing only subclinical, asymptomatic signs of infection - if vaccinated mothers with newborns do contract pertussis they will only think it's a slight cold and they will be less inclined to seek medical attention.

Nevermind that the vaccine has not been studied for safety in pregnant mothers and their fetus(es).

To date, one clinical trial was completed using pregnant mothers. The results are not published or available for review. The trial consisted of 48 pregnant woman and 32 non pregnant women. Both groups received a combination vaccine. Now, don't get me wrong, I'm not a clinical researcher - but the assessment of safety seems mute if both groups are receiving a vaccine with one not even pregnant to begin with. [21]


Research on this cocoon strategy is highly inefficient - and I'm going to go out on a limb here and say that it is also reckless.[22]




References:

[1] Weiss, A., Patton, A., Millen, S., Chang, S.j., Ward, J., Bernstein, D. Acellular pertussis vaccines and complement killing of bordetella pertussis. American Society for Microbiology (Infection and Immunity). Vol 72(12): 7346-7351. Dec 2004.

[2] WHO meeting on case definition of pertussis: Geneva 10-11 January, 1991. Geneva: World Health Organization, 1991:4-5 (issue no. MIN/EPI/PERT/91.1)

[3]Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from 10-year community study. BMJ 1988;296:612-4.

[4] Christie CD, Marx ML, Marchant CD, Reising SF. The 1993 epidemic of pertussis in Cincinnati: resurgence of disease in a highly immunized population of children. N Engl J Med 1994;331:16-21.

[5] Rosenthal S, Strebel P, Cassiday P, Sanden G, Brusuelas K, Wharton M. Pertussis infection in young adults during the 1993 outbreak in Chicago. J Infect Dis 1995;171:1650-2.

[6] De Melker HE, Conyn Van Spaendonck MA, Rumke HC, van Wijngaarden JK, Mooi FR, Schellekens JF. Pertussis in the Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg Infect Dis 1997;3:175-8.

[7] Yaari E, Yafe-Zimerman Y, Scwartz SB, Slater PE, Shvartzman P, Andoren N, et al. Clinical manifestations of Bordetella pertussis infection in immunized children and young adults. Chest 1999;115:1254-8

[8] I. Srugo, D. Benilevi, R. Madeb, S. Shapiro, T. Shohat, E. Somekh, Y. Rimmar, V. Gershtein, R. Gershtein, E. Marva, and N. Lahat. Pertussis Infection in Fully Vaccinated Children in Day-Care Centers, Israel. Emerging Infectious Diseases. Vol 6(5): 526-529. Sept/Oct 2000 PDF: http://wwwnc.cdc.gov/eid/article/6/5/pdfs/00-0512.pdf

 [9] Gráinne H. Long, Alexia T. Karanikas, Eric T. Harvill, Andrew F. Read and Peter J. Hudson. Acellular pertussis vaccination facilitates Bordetella parapertussis infection in a rodent model of bordetellosis. Proceedings of the Royal Society (Biological Sciences). Vol 277 (1690):2017-2025. Jul 2010

[10] Wolfe D, Goebel E, Bjornstad O, Restif O, Harvil E (2007). "The O Antigen Enables Bordetella parapertussis To Avoid Bordetella pertussis-Induced Immunity". Infection and Immunity 75 (10): 4972–9. doi:10.1128/IAI.00763-07. PMC 2044517. PMID 17698566. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2044517/.
[11] J. M. Bartkus, B. A. Juni, K. Ehresmann, C. A. Miller, G. N. Sanden, P. K. Cassiday, M. Saubolle,  B. Lee, J. Long, A. R. Harrison, Jr., and J. M. Besser. Identification of a Mutation Associated with Erythromycin Resistance in Bordetella pertussis: Implications for Surveillance of Antimicrobial Resistance. J Clin Microbiol. 2003 March; 41(3): 1167–1172.

[12] Vaccines and Antibiotic-Resistant Bacteria. National Network for Immunization Information. Dec 22, 2005

[13] Lallanilla, Marc. Antibiotic-Resistant Disease Crisis May Bring 'Apocalyptic Scenario,' UK Health Officer Says. Huffington Post (originally posted on Live-Science). Jan 25, 2013

[14] Nicola P. Klein, M.D., Ph.D., Joan Bartlett, M.P.H., M.P.P., Ali Rowhani-Rahbar, M.D., M.P.H., Ph.D., Bruce Fireman, M.A., and Roger Baxter, M.D.Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children. The New England Journal of Medicine. Sept 13, 2012. 367:1012-1019.

[15] Ori Hochwald, Ellen Bamberger and Issaac Srugo. The Return of Pertussis: Who is Responsible? What Can Be Done? Israel

[16]Vaccine Research Initiative. Vol 8: 301-307. May 2006[14]Nicholas Carbonetti. Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol. Vol 5: 455-469. Mar 2010

[17] Hewlett, Erik. Pertussis: current concepts of pathogenesis and prevention. Pediatric Infectious Disease Journal. Vol 16(4): S78-S84. Apr 1997

[18]Maxwell A. Wit1, Paul H. Katz, and David J. Witt. Unexpectedly Limited Durability of Immunity Following Acellular Pertussis Vaccination in Preadolescents in a North American Outbreak. Clinical Infectious Diseases. (Mar 2012) 54 (12: 1730-1735.

[19] Dooren, Jennifer.Panel Pushes Vaccine for Pregnant Women-Amid Whooping Cough Crisis, New Guidelines Recommend Mothers Get Vaccinated at Each Pregnancy. The Wallstreet Journal. Jan 28 2013.

[20] Boostrix package insert. GlaxoSmithKline

[21] Pertussis Vaccine in Healthy Pregnant Women. Sponsor: National Institute of Allergy and Infectious Diseases (NIAID). Clincila Trial ID # NCT00707148.

[22] Danuta M. Skowronski, Naveed Z. Janjua, Elodie P. Sonfack Tsafack, Manale Ouakki, Linda Hoang, and Gaston De Serres.The Number Needed to Vaccinate to Prevent Infant Pertussis Hospitalization and Death Through Parent Cocoon Immunization. Clinical Infectious Diseases. DEC 2011.



YOU Can Stop GMO Salmon from Reaching Your Plate

While you were unwrapping presents over your long Christmas vacation, genetically engineered salmon have met the final stage of FDA approval.

The Aquabounty’s salmon will be the first GE Animal approved for human consumption.

In April 2012, the FDA met assessments by all relevant agencies for approval but was blocked by congress because of safety and environmental concerns.

Last week, the White House has rescinded its order to block the FDA from Aquabounty’s GE Salmon approval.

One of the most concerning issues is the genetic integrity of the food chain. These genetically modified and engineered fish will be introduced into the natural eco system and mate with regular breeds and continue to create hybrid breeds, never being tracked. Another concern is that this salmon will not be labeled so consumers won’t know what they are buying.

Can you take action to keep genetically engineered salmon out of the
U.S.? Yes!

Click here to enter your zip code and find your congressman(woman). I wrote up this letter – simply copy and paste! Then pat yourself on the back and spread the word!


Dear Congressman,

I urge you to direct the FDA to reject the approval of Aquabounty's GE Salmon. The FDA does not currently have adequate safety testing to ensure that these animals will be safe for human health, wild fish populations and the environment.

Worst of all, while consumers have a right to know what's in their food and how it's being produced, under current law, these genetically engineered salmon would not have to be labeled.

There are numerous studies that address and support the health risks associated with, and evidenced by, unprecedented cancer rates caused by long term consumption of GMOs by laboratory animals.

There are long term studies that demonstrate the irrevocable and negative impacts on native populations of species (such as Africanized bees).

These genetically engineered animals should be rejected for consumer and environmental safety reasons.

Thank you for your consideration.



Would you like to read more before sending a email? Read this:



Polio-Information on Disease & Vaccine

This post is a continuation of a series that will be providing information on each disease and vaccine that is currently on the CDC’s recommended national immunization schedule.  I hope this information is able to help those attempting to decide on an alternative vaccine schedule (whether that is a delay, select or decline one). Please leave a comment if you have any questions.

The information below is gathered from sources included PubMed, the CDC, the Mayo Clinic, and package inserts published from the vaccine manufacturer. (See below for a full list) Be sure to check out the other posts on this series (Hepatitis B and Rotavirus).


The Disease

Polio or Poliomyelitis is derived from two Greek words: polio (grey) and myelon (marrow of the spinal cord). This name illustrates the effect poliomyelitis virus has on the spinal cord which leads to the characteristic paralysis we all associate with the disease. Interestingly, 95% of polio infection is subclinical meaning that the virus causes no symptoms.

The poliovirus is a member of the enterovirus subgroup which means that it has the ability to multiply in the gastrointestinal tract and is stable at an acid pH.

Humans are the only known reservoir for the virus.


Prevalence

At one point, transmission of poliovirus infection occurred around the globe. It has now been declared eradicated in the western hemisphere. Currently Pakistan, Afghanistan and Nigeria are the only countries where poliovirus is labeled as endemic (living within a geographical area).  

It is known that the ecology and herd immunity characteristics of polioviruses are heavily dependent upon levels of hygiene (pg 290). The poliovirus will mainly infect children under 5 years old and populations living in socioeconomically disadvantaged areas, where sanitation is poor and access to clean water is limited.

Wild polio viruses ceased to circulate in most of the United States by 1970, at which time only 65 percent of children were receiving a complete course of live oral polio vaccine. (Pg 290)

From 1923 to 1953, before the Salk killed-virus vaccine was introduced, the polio death rate in the United States and England had already declined on its own by 47 percent and 55 percent, respectively. Source: International Mortality Statistics (1981) by Michael Alderson.


Complications

A person’s response to a poliovirus infection can be highly variable and is categorized on the severity of their symptoms.

Nearly 95% of all poliovirus cases are asymptomatic or inapparent and less then 1% will lead to flaccid (reduced muscle tone) paralysis. Many people with paralytic polio will recover completely and the majority will experience muscle function return in various degrees.

1-2% of infected individuals will suffer from nonparalytic aseptic meningitis (stiffness of the neck, back or legs). Typically these symptoms will last from 2 to 10 days followed by a complete recovery.

Death rates for paralytic polio cases (remember this is <1% of cases) are approximately 2-5% for children with higher numbers seen in adults (15-30%). 



The Vaccines

I will only be discussing in detail the IPV (injectable polio) vaccines since the OPV (live, oral polio) vaccine is no longer employed in the US since 2000. This is due to the efforts to eliminate VAPP (vaccine-associated paralytic polio, aka polio caused by the oral vaccine).

It is believed that 90 percent of individuals who receive the polio vaccine will develop antibodies to all three polio virus types after two doses with 99% following the third dose. Protection is assumed and correlated with the presence of antibodies.

Because the injectable vaccine (IPV) produces less gastrointestinal immunity then the oral vaccine, persons who complete the schedule with the IPV are more readily infected with wild-type polio then OPV recipients.

Duration of immunity from IPV is not known, however it is assumed to provide “many years” of protection after the complete series is finished (according to the CDC).

There are three combination vaccines doctors use in the US that contain the inactivated polio vaccine. The acceptable schedule approved by the ACIP for IPV consists of four doses (2 months, 4months, 6-18 months, and 4 years). The first three doses are routinely administered with other vaccines.


IPOL (Sanofi Pasteur)

IPOL is the only singleton polio vaccine and can be used in children 6 weeks old to adulthood.

According to the package insert, interruption of the recommended schedule with a delay between doses does not interfere with the final immunity. There is no need to start the series over again, regardless of the time elapsed between doses.

Pediarix (GlaxoSmithKline)

Pediatrix contains DtaP, hepatitis B and IPV – this vaccine can be used for the first 3 doses (2month, 4month, 6-18 months) of the DtaP series among ages 6weeks through 6 years.

Each 0.5-mL dose contains aluminum as an adjuvant (not more than 850 mcg aluminum), ≤100 mcg of residual formaldehyde and ≤100 mcg of polysorbate 80 (Tween 80).

The safety study performed in the US for licensure consisted of a control group (335 infants) receiving the Hib conjugate vaccine (Wyeth; no longer licensed in the US) and 7-valent pneumococcal conjugate vaccine (Wyeth). No saline solution group was employed.

The rate of fever (greater then 100.4 degrees F) is significantly higher in the group that received Pediarix compared to separately administered vaccines. Other statistically significant adverse events include: pain, redness, swelling, drowsiness, irritability, and loss of appetite.

It is noted in the package insert that some cases of SIDS can be expected to follow receipt of pertussis-containing vaccines.


Kinrix (GlaxoSmithKline)

Kinrix contains DtaP and IPV – this vaccine is approved for children 4 yrs-6yrs which means that Kinrix is normally employed for the 5th dose of DtaP and fourth dose of IPV.

Each 0.5-mL dose contains aluminum as an adjuvant (not more than 60 mcg aluminum), ≤100 mcg of residual formaldehyde and ≤100 mcg of polysorbate 80 (Tween 80).

Adverse side effects reviewed in the clinical trials that were statistically significant were pain (statistically higher compared to IPOL), redness, swelling, drowsiness, loss of appetite and fever (statistically higher compared to IPOL). The placebo group used in clinical trials to assess safety was IPOL+Infanrix. No saline solution group was employed.


Pentacel (Sanofi Pasteur)

Pentacel contains DtaP, Hib and IPV – when this vaccine is used to provide the recommended 4 doses, an additional booster dose is suggested at age 4-6 years. This will result in a 5-dose IPV series.

Each 0.5 mL dose includes aluminum as an adjuvant  (330 mcg aluminum), polysorbate 80 (approximately 10 ppm by calculation), and ≤5 mcg  residual formaldehyde.

The placebo group used to assess safety was the Daptacel vaccine, Daptacel+IPOL+ActHIB and Daptacel+ActHIB. No saline solution group was employed.

Significant adverse events reviewed in the clinical trials were fever, decreased activity (lethargy), inconsolable crying and irritability.

Pentacel is the most reactive vaccine for polio. Serious adverse events 30 days after vaccination were reported more often then any other control groups in the safety assessment. Of these adverse reaction, events reported consist of: bronchiolitis, dehydration, pneumonia, asthma and gastroenteritis.



OPV

All of the vaccines listed above are inactivated poliovirus vaccines which do not contain live viruses, so they cannot cause VAPP (vaccine associated polio paralysis). However, the oral polio vaccine (OPV) is still administered to children and adults in countries around the world.

It is said that the advantages of using OPV in developing nations seem to outweigh the risk of vaccine-induced polio (the OPV is more cost effective). However, mutant strains (virus revertants) of vaccine-virus polio have been reported and have infected people in Hispaniola, the Philippines and Madagascar.


SV40 Contamination

SV40 (simian vacuolating virus 40) is a DNA-virus found in monkeys that has the potential to cause tumors. It was discovered in 1960, that same year SV40 was found to contaminate IPV vaccines.

That next year, in 1961, the virus was found to cause tumors in rodents. Following that discovery, the US government required new stocks of polio vaccine free of SV40.

The contaminated vaccines were not recalled and continued to be used for 3 more years following the discovery. Over 98 million US citizens received at least one dose of polio vaccine contaminated with SV40.

The current inactivatd polio vaccines (IPV) are free of contamination that we are curretly able to test for.


Whenever you make a health care decision for yourself or your child, especially one that involves a pharmaceutical product such as a vaccine, you should consider obtaining information from many different sources as well as consulting your health care professional.

Becoming an informed health care consumer is important and will empower you to ask doctors important questions and ultimately help you to take control of your health choices.

If your doctor is not supportive of your informed health choices, consider consulting another doctor who will work with you as a partner helping you make important health care decisions for yourself or your child(ren).



Information presented on this post can be reviewed in depth from the following sources:








Marx A, Glass JD, Sutter RW. Differential Diagnoses of Acute Flaccid Paralysis and It’s Role in Poliomyelitis Surveillance. Epidemiologic Reviews 2000; 22(2): 298-316.  

Preventing Another SV40 Tragedy: Are Today's Vaccine Safety Protocols Effective?  US House Government Reform Transcript, Nov 13, 2003

The SV-40 Virus: Has Tainted Polio Vaccine Caused an Increase in Cancer? US House Government Reform Subcommittee on Human Rights and Wellness: - Sept 10, 2003